Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi Bio’s NDA for COVID-19 Therapy Accepted for Review in China

publication date: Jan 24, 2023

Shanghai Junshi Biosciences’ NDA for a COVID-19 treatment has been accepted for review by China’s NMPA. The Deuremidevir Hydrobromide Tablet, known as VV11, is an oral nucleoside analog anti-SARS-CoV-2 drug that inhibits the replication of SARS-CoV-2. In a Phase III trial, it lowered recovery time compared to Pfizer’s Paxlovid, the current standard of care. VV116 was developed by a network of China government institutes, including the Shanghai Institute of Materia Medica, plus Suzhou Vigonvita Life Sciences and Junshi Bio. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital